The relationship between calcification inhibitor levels in chronic kidney disease and the development of atherosclerosis

References

• Tonelli M, Wiebe N, Culleton B, et al. Chronic kidney disease and mortality risk: a systematic review. JASN. 2006;17(7):2034–2047.
   Web of Science ®Google Scholar
• Kendrick J, Chonchol MB. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease. Nat Clin Pract Nephrol. 2008;4(12):672–681.
   PubMedGoogle Scholar
• Sarnak MJ, Coronado BE, Greene T, et al. Cardiovascular disease risk factors in chronic renal insufficiency. CN. 2002;57(05):327–335.
   Google Scholar
• Suliman ME, García-López E, Anderstam B, et al. Chapter 6 vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on Fetuin-A in chronic kidney disease. Adv Clin Chem. 2008;46:217–262.
   Google Scholar
• Ketteler M, Westenfeld R, Schlieper G, et al. Pathogenesis of vascular calcification in dialysis patients. Clin Exp Nephrol. 2005;9(4):265–270.
   PubMedGoogle Scholar
• Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int. 2005;67(6):2295–304.
   PubMed Web of Science ®Google Scholar
• Smith ER. Vascular calcification in uremia: new-age concepts about an old-age problem. Methods Mol Biol. 2016;1397:175–208.
   PubMedGoogle Scholar
• Collado S, Coll E, Nicolau C, et al. Cases, A. Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function. BMC Nephrol. 2017;18(1):290.
   PubMedGoogle Scholar
• Disthabanchong S, Srisuwarn P. Mechanisms of vascular calcification in kidney disease. Adv Chronic Kidney Dis. 2019;26(6):417–426.
   PubMed Web of Science ®Google Scholar
• Pateinakis P, Papagianni A, Douma S, et al. Associations of fetuin-A and osteoprotegerin with arterial stiffness and early atherosclerosis in chronic hemodialysis patients. BMC Nephrol. 2013;14(1):122.
   PubMedGoogle Scholar
• Hodis HN, Mack WJ, LaBree L, et al. The role of carotid arterial Intima – media thickness in predicting clinical coronary events. Ann Intern Med. 1998;128(4):262–269.
   PubMed Web of Science ®Google Scholar
• Keith DS, Nichols GA, Gullion CM, et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659–663.
   PubMed Web of Science ®Google Scholar
• Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000;356(9224):147–52.
   PubMed Web of Science ®Google Scholar
• Prichard S. Risk factors for coronary artery disease in patients with renal failure. Am J Med Sci. 2003;325(4):209–213.
   PubMed Web of Science ®Google Scholar
• Fakhry M, Sidhu MS, Bangalore S, et al. Accelerated and intensified calcific atherosclerosis and microvascular dysfunction in patients with chronic kidney disease. Rev Cardiovasc Med. 2020;21(2):157–162.
   PubMed Web of Science ®Google Scholar
• Geroulakos G, O’Gorman DJ, Kalodiki E, et al. The carotid intima-media thickness as a marker of the presence of severe symptomatic coronary artery disease. Eur Heart J 1994;15(6):781–785.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Fried LF, Stehman-Breen C, et al. Chronic renal insufficiency and cardiovascular events in the elderly: findings from the cardiovascular health study. Amer J Geriatric Cardiol. 2004;13(2):81–90.
   PubMedGoogle Scholar
• Vanholder R, Massy Z, Argiles A, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005;20(6):1048–56.
   PubMed Web of Science ®Google Scholar
• Baldassarre D, Amato M, Bondioli A, et al. Carotid artery intima-media thickness measured by ultrasonography in normal clinical practice correlates well with atherosclerosis risk factors. Stroke. 2000;31(10):2426–2430.
   PubMed Web of Science ®Google Scholar
• Makita S, Abiko A, Naganuma Y, et al. Chronic kidney disease is associated with increased carotid artery stiffness without morphological changes in participants of health check-up programs. Atherosclerosis. 2010;213(1):306–310.
   PubMed Web of Science ®Google Scholar
• Modi N, Kapoor A, Kumar S, et al. Utility of carotid intimal medial thickness as a screening tool for evaluation of coronary artery disease in pre-transplant end stage renal disease. J Postgrad Med. 2006;52(4):266–70.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol. 2003;14(7):1927–1939.
   PubMed Web of Science ®Google Scholar
• Perazella MA, Khan S. Increased mortality in chronic kidney disease: a call to action. Am J Med Sci. 2006;331(3):150–3.
   PubMed Web of Science ®Google Scholar
• Kovesdy CP, Anderson JE. Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis. Semin Dial. 2007;20(6):566–569.
   PubMed Web of Science ®Google Scholar
• Stenvinkel P, Carrero JJ, Axelsson J, et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol. 2008;3(2):505–521.
   PubMed Web of Science ®Google Scholar
• Proudfoot D, Skepper JN, Shanahan CM, et al. Calcification of human vascular cells in vitro is correlated with high levels of matrix gla protein and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol. 1998;18(3):379–388.
   PubMed Web of Science ®Google Scholar
• London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol. 2003;14(suppl 4):S305–S309.
   PubMedGoogle Scholar
• Kramer H, Toto R, Peshock R, et al. Association between chronic kidney disease and coronary artery calcification: the Dallas heart study. J Am Soc Nephrol. 2005;16(2):507–513.
   PubMed Web of Science ®Google Scholar
• Derici U, El Nahas AM. Vascular calcifications in uremia: old concepts and new insights. Semin Dial. 2006;19(1):60–68.
   PubMed Web of Science ®Google Scholar
• Dellegrottaglie S, Sanz J, Rajagopalan S. Molecular determinants of vascular calcification: a bench to bedside view. Curr Mol Med. 2006;6(5):515–24.
   PubMed Web of Science ®Google Scholar
• Rucker D, Tonelli M. Cardiovascular risk and management in chronic kidney disease. Nat Rev Nephrol. 2009;5(5):287–296.
   PubMed Web of Science ®Google Scholar
• Jahnen-Dechent W, Schinke T, Trindl A, et al. Cloning and targeted deletion of the mouse fetuin gene. J Biol Chem. 1997;272(50):31496–31503.
   PubMed Web of Science ®Google Scholar
• Hermans MMH, Brandenburg V, Ketteler M, et al. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int. 2007;72(2):P202–207.
   PubMed Web of Science ®Google Scholar
• Wang AYM, Woo J, Lam CWK, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant. 2005;20(8):1676–85.
   PubMed Web of Science ®Google Scholar
• Mutluay R, Konca Değertekin C, Işiktaş Sayilar E, et al. Serum fetuin-A is associated with the components of miac (malnutrition, inflammation, atherosclerosis, calcification) syndrome in different stof chronic kidney disease. Turkish J Med Sci. 2019;49(1):327–335.
   PubMed Web of Science ®Google Scholar
• Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361(9360):827–33.
   PubMed Web of Science ®Google Scholar
• Kuźniar J, Porazko T, Klinger M. Relationship between fetuin-A concentration, elevated levels of inflammatory markers, and arterial wall stiffness in end-stage kidney disease. J Ren Nutr. 2008;18(1):83–86.
   PubMed Web of Science ®Google Scholar
• Farzaneh-Far A, Proudfoot D, Weissberg PL, et al. Matrix gla protein is regulated by a mechanism functionally related to the calcium-sensing receptor. Biochem Biophys Res Commun. 2000;277(3):736–740.
   PubMed Web of Science ®Google Scholar
• Jaminon AMG, Dai L, Qureshi AR, et al. Matrix gla protein is an independent predictor of both intimal and medial vascular calcification in chronic kidney disease. Sci Rep. 2020;10(1):6586.
   PubMed Web of Science ®Google Scholar
• Nascimento MM, Hayashi SY, Riella MC, et al. Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease. Brazilian J Med Biol Res. 2014;47(11):995–1002.
   PubMed Web of Science ®Google Scholar
• Huang QX, Li JB, Huang N, et al. Elevated osteoprotegerin concentration predicts increased risk of cardiovascular mortality in patients with chronic kidney disease: a systematic review and meta-analysis. Kidney Blood Press Res. 2020;45(4):565–575.
   PubMed Web of Science ®Google Scholar